Regeneron Pharmaceuticals, Inc. (REGN) Stock Valuation — PE Analysis
Biotechnology · NASDAQ
Current Price
$695.42
PE Ratio (TTM)
16.6x
Intrinsic Value
$1,080.55
+35.6% margin of safety
COMPETITIVE MOAT
↑Proprietary Drug Pipeline
Regeneron's success hinges on its innovative drug discovery and development platform, leading to a strong pipeline of novel therapeutics.
↑Scientific Expertise & Talent
The company attracts and retains top scientific talent, fostering a culture of innovation crucial for sustained R&D breakthroughs.
↑Established Market Position
Successful commercialization of key drugs like Eylea and Dupixent creates significant market share and brand recognition.
INVESTMENT RISKS
↓Clinical Trial Failures
The inherent risk of drug development means that promising candidates can fail in late-stage trials, impacting future revenue.
↓Pricing Pressures & Reimbursement
Increasing scrutiny on drug pricing and evolving reimbursement policies from payers can affect profitability.
↓Dependence on Key Products
Over-reliance on a few blockbuster drugs for a significant portion of revenue creates vulnerability if those products face challenges.
Base case
REGN base case PE valuation
A base case PE valuation for REGN estimates a fair value of about $1,080.55 per share, against a current price of $695.42. The model assumes 13.9% annual earnings growth, a 17x target PE multiple, and a 10% discount rate.
Intrinsic Value
$1,080.55
Margin of safety
+35.6%
Expected annual return
+9.2%
Base case assumptions: 13.9% annual earnings growth, 17x target PE, 10% discount rate, 5 year projection. Data as of 2026-07-29.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the REGN PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Regeneron Pharmaceuticals, Inc. respond.
Open PE Calculator for REGNCompany Overview
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Financial Metrics — REGN PE Stock Valuation Data
PE Ratio (TTM)
16.6x
PEG Ratio
53.33
Earnings Yield
6.02%
ROE (TTM)
13.1%
Revenue/Share (TTM)
$150.24
Dividend Yield
0.52%
Debt/Equity
0.05x
Frequently Asked Questions
What is the PE ratio of REGN?
The trailing twelve-month PE ratio of REGN reflects how much investors pay per dollar of Regeneron Pharmaceuticals, Inc.'s earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.
Is REGN overvalued based on PE ratio?
REGN's PE of 16.6x combined with a PEG ratio of 53.33 provides a growth-adjusted perspective. A PEG above 2.0 means the P/E is high relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.
How do I value REGN stock using PE ratio?
To value Regeneron Pharmaceuticals, Inc. using PE: (1) Compare the current PE (16.6x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (53.33) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of REGN?
REGN's PEG ratio is 53.33, calculated by dividing the PE ratio (16.6x) by the expected earnings growth rate. A PEG above 2.0 means the P/E is high relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for REGN stock valuation?
PE ratio gives a quick relative read — how REGN is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See REGN DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value REGN with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-07-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.